Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161.6 USD | +0.19% | -0.59% | +4.27% |
05-13 | AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders | MT |
05-09 | Medincell: share price rises on resumption of trading | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 285B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B | |
-1.42% | 161B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie Says Phase 3 Trial of Atogepant for Episodic Migraine Met Primary, Secondary Endpoints